New imaging solution for prostate cancer detection

I’m very excited to share that our paper, “Prostate-specific membrane antigen positron emission tomography/computed tomography imaging as a precision diagnostic at prostate cancer recurrence after radical prostatectomy: Modeling long-term survival,” has just been published in CANCER, part of the American Cancer Society Journals. PSMA-PET/CT is affecting the management of patients with prostate cancer with biochemical recurrence after radical prostatectomy. However, the long-term outcomes of tailoring salvage treatment on the basis of PSMA-PET/CT status remain to be determined. In this study, we developed a decision-analytic modeling framework to project long-term outcomes based on short-term PSMA-PET/CT findings and corresponding treatment decisions. In the absence of survival outcomes by PSMA-PET/CT status, this framework permits the projection of a range over the expected incremental survival benefit under tailored management strategies.The modeling framework we present here also applies more broadly to precision oncology settings, where a novel diagnostic enables additional risk stratification and treatment personalization. Our model projections might also complement emerging data on the corresponding economic costs and health-related quality of life. While we await results from empirical studies on long-term outcomes, our modeling framework may help clarify key factors driving the impact of precision diagnostics like PSMA-PET/CT. You can access the article here: https://lnkd.in/g_zKZCjS #PSMAPET #ProstateCancer #PrecisionOncology #DecisionModeling #OutcomesResearch

A retrospective study found 99mTc-PSMA-I ","S SPECT/CT achieved 100% sensitivity, 77.78% specificity and 95.83% accuracy in detecting primary prostate cancer. SUVmax values correlated with Gleason score, PSA levels, risk stratification and metastatic status. "SUVmax serves as a robust predictor for risk stratification and metastatic potential assessment," researchers wrote in Frontiers in Medicine.

Stereotactic Tumor Irradiation Improves Progression-Free Survival in Locally Advanced NSCLC In a multicenter retrospective study published in the International Journal of Radiation Oncology • Biology • Physics (Red Journal), Etienne Cedoz and colleagues evaluated tumor stereotactic body radiotherapy (T-SBRT) compared with standard normofractionated chemoradiotherapy (NFRT) in patients with unresectable locally advanced non–small cell lung cancer (LA-NSCLC) treated with durvalumab maintenance. Among 208 patients (median age 64 years), 21 received T-SBRT (most commonly 50 Gy in 5 fractions). After a median follow-up of 38 months, T-SBRT was associated with significantly longer progression-free survival (HR = 0.46, p = 0.046) and a trend toward improved overall survival without increased grade 3–5 toxicity. These results suggest that tumor-focused dose intensification via SBRT, in combination with modern immunotherapy, could improve disease control in selected patients with LA-NSCLC. This study was made possible through collaboration among multiple French radiation oncology centers and the dedicated contributions of radiation oncologists, medical physicists, and data scientists involved in patient care and data analysis. Read more:https://lnkd.in/dJ7Ragqc #LungCancer #RadiationOncology #SBRT #NSCLC #Durvalumab #Immunotherapy #OncologyResearch #ASTRO #PrecisionRadiation #CancerTreatment #ClinicalResearch

A newly identified subtype of brain tumor, IME IDH-mutant astrocytoma, demonstrates high immune activity yet is linked to poorer survival outcomes, challenging the assumption that “immune-hot” tumors have better prognoses. Researchers have developed an AI-based platform, GUIDE, to accurately classify this subtype by integrating imaging and multi-omics data. This advancement enables more precise patient stratification and supports the development of targeted therapies, highlighting the importance of molecular profiling in improving outcomes for patients with diffuse gliomas. The findings underscore the complexity of tumor biology and the need for personalized treatment strategies.

💊 A major clinical trial led by researchers at Karolinska Institutet, Karolinska University Hospital, and SciLifeLab shows that low-dose aspirin reduces the risk of relapse in stage I–III colorectal cancer by ~50%, specifically in patients with PI3K pathway mutations. 🧬 The #ALASCCA trial is a landmark example of how genomics can guide treatment decisions. Tumor samples were sequenced at the Clinical Genomics platform to identify patients with PI3K mutations. The results are now published in the New England Journal of Medicine. 💡 The team is now working to translate the ALASCCA analysis into a routine clinical test at Karolinska University Hospital. “The ALASCCA trial is probably one of the best examples of research, driven entirely by an academic research team, going from bench to bedside. Just with a short delay, the result of the trial will benefit patients outside of the trial.” says Valtteri Wirta, Platform Scientific Director, Clinical Genomics https://lnkd.in/d5g39Eex

Revealing how adipose-derived extracellular vesicles promote breast cancer progression: in their latest work, Maria Pia Cavaleri, barbara zavan at University of Ferrara, Letizia Ferroni at GVM Care & Research and collaborators elucidated the mechanisms by which adipocyte-derived extracellular vesicles influenced breast cancer (BC) progression. Human mesenchymal stem cells (hMSCs) were differentiated into adipocytes through a 21-day induction protocol, resulting in a marked accumulation of lipid droplets. EVs were subsequently isolated from the conditioned media of both hMSC-derived adipocytes and BC cells. Interferometric Light Microscopy (ILM, Videodrop), transmission electron microscopy, and fluorescence microscopy were employed to assess particle size distribution, morphology, and cellular uptake, respectively 🔗 https://lnkd.in/ehR6CVEm Their results revealed that BC-derived EVs reduced stromal cell viability and altered the expression of apoptosis-related genes, enhancing resistance to cell death. Conversely, stromal-derived EVs significantly modulated tumor cell behavior, demonstrating a dynamic, bidirectional exchange of molecular signals. Overall, their findings highlighted the critical role of EV-mediated communication in the tumor–stroma interplay, suggesting that adipocyte–cancer cell EV crosstalk actively reshaped the tumor microenvironment and promoted tumor progression. An article co-authored by Tommaso Pusceddu, Lucia Sileo, Luna Ardondi, Ilaria Vitali, Ilenia Cappucci, Laura Basile, Giuseppe Pezzotti and Francesco Fiorica. #extracellularvesicles #exosomes #adipocyte #breastcancer #Vesiculab

🧠 Highlights from the EORTC - European Organisation for Research and Treatment of Cancer Brain Tumor Group at #EANO2025 | Prague 🇨🇿 It’s inspiring to see the continued innovation and collaboration within the EORTC Brain Tumor Group (BTG), pushing the boundaries of neuro-oncology through high-quality, practice-changing clinical trials. Here are some of the current key studies presented: 🔹 EORTC 2227 – LEGATO ➡️ Lomustine with and without reirradiation for first progression of glioblastoma A phase III randomized trial (n=411) investigating whether reirradiation adds benefit to lomustine alone in recurrent GBM - Already open and recruiting. 🔹 EORTC LUMEN-1 ➡️ 177Lu-DOTATATE for recurrent meningioma Phase II randomized (2:1) study evaluating targeted radionuclide therapy for SSTR-positive recurrent meningioma – an exciting precision approach - Already open and recruiting. 🔹 EORTC 2427-BTG (VIGOR) ➡️ Vorasidenib as maintenance therapy in IDH-mutant grade 2/3 astrocytoma Triple-blind, placebo-controlled phase III study assessing long-term benefit of maintenance therapy after first-line chemoradiotherapy - Planned FPI in Dec 2025. 🔹 EORTC 2013 (GLIO-RARE) ➡️ Observational registry for rare and molecularly defined primary brain tumors Comprehensive prospective and retrospective data collection across 17 cohorts — aligning with the latest 2021 WHO classification and CIMPACT-NOW framework. 🌍 These studies reflect the strength of international collaboration and the commitment to improving outcomes for patients with both common and rare brain tumors. 👏 Kudos to all investigators, coordinators, and participating centers contributing to these impactful efforts under the EORTC and EANO umbrellas. #NeuroOncology #ClinicalResearch #EORTC #BrainTumorResearch #EANO2025 #Glioblastoma #Meningioma #Astrocytoma #InnovationInCancerCare

New publication: Ultra-Fast Intraoperative IDH-Mutation Analysis Enables Rapid Stratification and Therapy Planning in Diffuse Gliomas A prospective study from University Hospital Salzburg reports that IDH testing on Idylla™ returned results in ~90 minutes and matched NGS 1:1 across FFPE and fresh/snap-frozen glioma samples. IHC missed non-canonical variants that the cartridge caught. This kind of turnaround could enhance surgical and therapeutic strategies, enabling same-day tumor board decisions and earlier use of targeted options for IDH-mutant disease "In summary, the Idylla IDH-mutation system delivers ultra-fast and reliable results of both FFPE and snap-frozen/native-tissue samples in the setting of routine and intraoperative histological assessment with 100% concordance with routine NGS diagnostics” "Incorporating such rapid assays into intraoperative decision-making processes has the potential to enhance surgical and therapeutic strategies” #glioma #molecular #oncology #idylla

MRI Before Biopsy: A Safer, Smarter Pathway for Prostate Cancer Diagnosis A landmark study published in JAMA Oncology provides strong evidence supporting the oncological safety of MRI-informed biopsy decisions in men with suspected prostate cancer. Key findings (3-year follow-up, n=593): + 48% of men had negative MRI results + 86% of those with negative MRI safely avoided biopsy + Only 4% developed clinically significant cancer during follow-up — all under active monitoring The message is clear: pre-biopsy MRI can help avoid unnecessary procedures without compromising patient safety — when combined with structured monitoring. This aligns with a broader shift in radiology from reactive diagnostics to risk-based prevention — where imaging becomes a gatekeeper, not a downstream test. As MRI technology, AI triage tools, and precision workflows continue to evolve, personalized imaging pathways like this could redefine how we approach cancer detection — focusing on relevance, not routine. Source: Hamm CA, Asbach P, Pöhlmann A, et al. Oncological Safety of MRI-Informed Biopsy Decision-Making in Men With Suspected Prostate Cancer. JAMA Oncol. 2025;11(2):145–153. doi:10.1001/jamaoncol.2024.5497 #Radiology #MRI #ProstateCancer #PrecisionMedicine #PreventativeHealth #OncologyImaging #FutureOfRadiology #PatientCare #ClinicalResearch #JAMAOncology #Amriscan Peter R. Seidensticker

Experimental Glioblastoma Trial Findings Could Lead to Change in Patient Monitoring and Therapy Multiomics analysis of serial tumor biopsies from glioblastoma involved in an immunotherapy trial allowed scientists to safely monitor tumor progression and therapeutic response, capturing details not discernible by advanced imaging methods. E. Antonio Chiocca, Harvard Medical School, Mass General Brigham Pedro R. Lowenstein, University of Michigan #BrainCancer #glioblastoma #immunotherapy #omics